Dora Visnjic
Overview
Explore the profile of Dora Visnjic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smoljo T, Lalic H, Dembitz V, Tomic B, Batinic J, Vrhovac R, et al.
Am J Physiol Cell Physiol
. 2024 Sep;
327(5):C1202-C1218.
PMID: 39279497
Acute myeloid leukemia (AML) is a heterogeneous group of hematological malignancies characterized by differentiation arrest, high relapse rates, and poor survival. The bone marrow (BM) microenvironment is recognized as a...
2.
Smoljo T, Tomic B, Lalic H, Dembitz V, Batinic J, Bedalov A, et al.
Front Pharmacol
. 2023 Nov;
14:1258151.
PMID: 37954840
Low-dose cytarabine (LDAC) is a standard therapy for elderly acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. While high doses of cytarabine induce cytotoxicity, the precise mechanism of action...
3.
Tomic B, Smoljo T, Lalic H, Dembitz V, Batinic J, Batinic D, et al.
Sci Rep
. 2022 Jul;
12(1):11344.
PMID: 35790845
Acute myeloid leukemia (AML) is characterized by arrested differentiation making differentiation therapy a promising treatment strategy. Recent success of inhibitors of mutated isocitrate dehydrogenase (IDH) invigorated interest in differentiation therapy...
4.
Lalic H, Aurer I, Batinic D, Visnjic D, Smoljo T, Babic A
Oncol Rep
. 2022 May;
47(6).
PMID: 35506458
Bendamustine is an alkylating agent classified into the group of nitrogen mustard analogues, synthesized almost sixty years ago. It was registered in former East Germany in 1971 and approved by...
5.
Dembitz V, Lalic H, Tomic B, Smoljo T, Batinic J, Dubravcic K, et al.
Int J Hematol
. 2021 Sep;
115(1):43-53.
PMID: 34546543
All-trans retinoic acid (ATRA)-based therapy for acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), is the most successful example of differentiation therapy. Although ATRA can induce differentiation...
6.
Visnjic D, Lalic H, Dembitz V, Tomic B, Smoljo T
Cells
. 2021 Jun;
10(5).
PMID: 34064363
5-Aminoimidazole-4-carboxamide ribonucleoside (AICAr) has been one of the most commonly used pharmacological modulators of AMPK activity. The majority of early studies on the role of AMPK, both in the physiological...
7.
Klionsky D, Abdel-Aziz A, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, et al.
Autophagy
. 2021 Feb;
17(1):1-382.
PMID: 33634751
In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our...
8.
Dembitz V, Lalic H, Kodvanj I, Tomic B, Batinic J, Dubravcic K, et al.
BMC Cancer
. 2020 Nov;
20(1):1090.
PMID: 33176741
Background: All-trans retinoic acid (ATRA)-based treatment of acute promyelocytic leukemia (APL) is the most successful pharmacological treatment of acute myeloid leukemia (AML). Recent development of inhibitors of mutated isocitrate dehydrogenase...
9.
Dembitz V, Tomic B, Kodvanj I, Simon J, Bedalov A, Visnjic D
J Biol Chem
. 2019 Aug;
294(42):15257-15270.
PMID: 31431503
Metabolic pathways play important roles in proliferation and differentiation of malignant cells. 5-Aminoimidazole-4-carboxamide ribonucleoside (AICAr), a precursor in purine biosynthesis and a well-established activator of AMP-activated protein kinase (AMPK), induces...
10.
Visnjic D, Dembitz V, Lalic H
Curr Med Chem
. 2018 Jan;
26(12):2208-2229.
PMID: 29345570
Differentiation therapy of acute promyelocytic leukemia with all-trans retinoic acid represents the most successful pharmacological therapy of acute myeloid leukemia (AML). Numerous studies demonstrate that drugs that inhibit mechanistic target...